Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q1 FY23 results · Apr–Jun 2022
Solara Active Pharma Sciences reported revenue from operations of ₹330.07 crore (down 18.6% from Q1 FY22) and net loss of ₹16.45 crore for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 330.07 | 405.57 | −18.6% | 360.82 | −8.5% |
| Other income | 6.98 | 5.91 | +18.1% | 6.07 | +15.0% |
| Total income | 337.05 | 411.48 | −18.1% | 366.89 | −8.1% |
| Profit before tax | (31.10) | 50.11 | Turned loss | (31.00) | Loss widened |
| Net profit for the period | (16.45) | 50.11 | Turned loss | 1.81 | Turned loss |
| Attributable to shareholders of the company | (16.43) | 50.07 | Turned loss | 1.88 | Turned loss |
| EPS, basic (₹) | (4.56) | 13.95 | Turned loss | 0.53 | Turned loss |
| Net margin (%) | -5.0 | 12.4 | 0.5 |
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 330.07 | 405.57 | −18.6% | 360.82 | −8.5% |
| Other income | 6.48 | 5.80 | +11.7% | 4.69 | +38.2% |
| Total income | 336.55 | 411.37 | −18.2% | 365.51 | −7.9% |
| Profit before tax | (34.39) | 50.56 | Turned loss | (32.88) | Loss widened |
| Net profit for the period | (19.18) | 50.56 | Turned loss | 0.22 | Turned loss |
| EPS, basic (₹) | (5.33) | 14.07 | Turned loss | 0.06 | Turned loss |
| Net margin (%) | -5.8 | 12.5 | 0.1 |
Consolidated
- Filed with BSE
- 05 Aug 2022, 11:04 IST
- Board meeting
- 04 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 Aug 2022, 11:04 IST
- Board meeting
- 04 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE